FDA Reviewing Cancer Trial Endpoints, Oncology Director Pazdur Tells ASCO
Executive Summary
FDA's Division of Oncologic Drug Products will conduct an internal review of regulatory endpoints for cancer trials, division Director Richard Pazdur, MD, said May 13 during the American Society of Clinical Oncology annual meeting in San Francisco.
You may also be interested in...
Cancer Survival And Symptom Trials May Be "Ideal Drug Package" - Pazdur
Submission of one cancer survival trial and one symptom trial for approval of oncologic agents would be considered optimal by FDA, Oncologic Drug Products Division Director Richard Pazdur, MD, said.
Cancer Survival And Symptom Trials May Be "Ideal Drug Package" - Pazdur
Submission of one cancer survival trial and one symptom trial for approval of oncologic agents would be considered optimal by FDA, Oncologic Drug Products Division Director Richard Pazdur, MD, said.
Roche Xeloda Colorectal Use Clears FDA; Promotions Must Cite Camptosar
Roche will study Xeloda in combination with Pharmacia's Camptosar in colorectal cancer patients following FDA approval of Xeloda April 30 for use in metastatic colorectal cancer patients.